336 Views | 158 Downloads
Marc I. Chimowitz, MBChB, Medical University of South Carolina Stroke Program, 19 Hagood Ave., Harborview Office Tower, Suite 501, Charleston, SC 29425, phone: 843-792-3020, fax: 843-792-2484, mchimow@musc.edu.
All the authors serve on the Executive Committee of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial which is funded by the National Institute of Neurological Disorders and Stroke (grant number: U01 NS058728).
All but one (SJ) receive salary support from the SAMMPRIS grant.
See publication for full list of disclosures.
The SAMMPRIS trial was funded by a research grant (U01 NS058728) from the US Public Health Service National Institute of Neurological Disorders and Stroke (NINDS).
In addition, the following Clinical and Translational Science Awards, funded by the National Institutes of Health, provided local support for the evaluation of patients in the trial: Medical University of South Carolina (UL1RR029882), University of Florida (UL1RR029889), University of Cincinnati (UL1RR029890), and University of California, San Francisco (UL1RR024131).
Stryker Neurovascular (formerly Boston Scientific Neurovascular) provided study devices and supplemental funding for third party device distribution, site monitoring and study auditing.
This research is also supported by the Investigator-Sponsored Study Program of AstraZeneca that donates rosuvastatin (Crestor) to study patients.